In contrast, recent studies have highlighted that PPARγ antagonists ameliorated high-fat diet (HFD)-induced obesity, insulin resistance and fatty liver disease by inhibiting lipogenesis15, 16, 17, 18, 19, 20, 21. The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.